Cohbar started at buy with $3 stock price target at Maxim Group

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Cohbar Inc.

CohBar, Inc. engages in the research and development of mitochondria-based therapeutics. It focuses on treatments of diseases, which include diabetes, obesity, fatty liver disease and non-alcoholic steatohepatitis, cancer, Alzheimer’s disease, and atherosclerosis. The company was founded by Nir Barzilai, Pinchas Cohen, David Sinclair, John Amatruda, and Laura Cobb on October 19, 2007 and is headquartered in Menlo Park, CA.

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Leave a Reply